Group 1 - The sixth session of the Supervisory Board of Nanjing Baose Co., Ltd. held its tenth meeting on June 13, 2025, via communication methods, with all five supervisors present [1][2]. - The Supervisory Board approved the temporary use of up to 200 million yuan of idle raised funds to supplement working capital, which is expected to meet the company's daily operational funding needs and reduce financial expenses [1][2]. - The decision to use part of the idle raised funds does not conflict with the implementation plan of the investment projects funded by the raised capital and is in the interest of the company and all shareholders [1][2]. Group 2 - The voting results of the meeting were unanimous, with 5 votes in favor, 0 against, and 0 abstentions [2]. - The announcement regarding the use of idle raised funds was also published on the designated information disclosure website of the China Securities Regulatory Commission [2]. - The meeting and its resolutions complied with relevant regulations, ensuring legality and effectiveness [1].

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Core Points - The company held its 2025 second meeting of the 11th Board of Directors on June 6, 2025, via communication voting [1] - The board approved the addition of members to certain specialized committees [1] - The board also approved the temporary use of idle raised funds amounting to 213.5 million yuan to supplement the company's working capital [1][2] Group 1 - The board meeting was conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the resolutions [1] - The resolution for the addition of committee members received unanimous support with 7 votes in favor [1] - The resolution to use idle funds aims to enhance the efficiency of fund utilization and reduce operational costs while ensuring the needs of investment projects are met [1] Group 2 - The temporary use of 213.5 million yuan is intended to support the company's and its subsidiaries' working capital needs for a period not exceeding 12 months [1] - The decision reflects the company's commitment to maximizing shareholder interests [1]

Group 1 - The company plans to raise a total of no more than 900 million yuan through a private placement of A-shares, with all proceeds intended to supplement working capital after deducting issuance costs [1] - The necessity of the fundraising is highlighted by the company's rapid business expansion, with revenue growth rates of 661.33%, 84.46%, and 33.13% in recent years, indicating a strong demand for operational funds in the high-tech biopharmaceutical and vaccine sectors [1][2] - The company has a significant historical investment in R&D, with expenditures of 973 million yuan, 1.217 billion yuan, and 936 million yuan for the years 2022, 2023, and 2024 respectively, and cumulative losses reaching 3.76 billion yuan as of March 31, 2025 [2] Group 2 - The issuance of new shares is expected to enhance the company's financial strength, reduce the debt-to-asset ratio, and improve liquidity, thereby increasing operational safety and asset fluidity [2][3] - The company has established a modern corporate governance structure and a clear management framework for the use of raised funds, ensuring compliance with relevant laws and regulations [3] - Following the completion of the issuance, both total assets and net assets will increase, further improving the company's financial condition and risk resistance capabilities [4]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 炬申物流集团股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日召开 了第三届董事会第三十二次会议及第三届监事会第二十七次会议，审议通过了 《关于使用部分暂时闲置的募集资金暂时补充流动资金的议案》，同意公司在不 影响募集资金项目正常进行的前提下使用暂时闲置募集资金不超过人民币 2000 万元暂时补充流动资金，使用期限自董事会审议通过之日起不超过十二个月。在 上述额度及期限内，资金可以循环使用，到期或募集资金投资项目需要时及时归 还至募集资金专用账户。同时，董事会同意公司开设相应的募集资金专项账户， 用于暂时补充流动资金募集资金的存储与使用，并授权管理层办理后续与保荐机 构、募集资金存放银行签订募集资金三方监管协议以及其他相关事宜。具体内容 如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准炬申物流集团股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕1117 号）核准，公司向社会公开发行人民 币普通股（A股）3,224.20 万股，本次公开发行人民币普通股每股面值为人民币 万 ...

Meeting Overview - The second meeting of the Supervisory Board of Guangdong Oulai High-tech Materials Co., Ltd. was held on May 23, 2025, using a combination of on-site and remote voting methods [1] - The meeting was convened by the Chairman of the Supervisory Board, Mr. Guo Wenming, and all three supervisors attended [1] - The meeting complied with relevant laws and regulations, including the Company Law of the People's Republic of China and the listing rules of the Shanghai Stock Exchange [1] Meeting Resolutions - The Supervisory Board agreed to use part of the temporarily idle raised funds for cash management, which is expected to improve the efficiency of fund usage, reduce financial costs, and increase cash asset returns [2][3] - The decision aligns with the interests of the company and all shareholders, and it will not affect the normal implementation of fundraising projects [2][3] - The voting results were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2][3]

Fundraising Plan - The company plans to raise a total of up to 500 million yuan through a private placement of A-shares, with all proceeds intended to supplement working capital after deducting issuance costs [1][2] Necessity and Feasibility Analysis - The global lithium salt industry is experiencing accelerated differentiation in supply and demand, with a significant market capacity for future product demand growth [1] - The company aims to establish a supply chain security system by focusing on resource development efficiency and cost control, while also optimizing processes and driving technological innovation [1] - The fundraising will support the company's supply chain resource layout and technology research and development, enhancing its core competitiveness [1] Impact on Management and Financial Status - The fundraising will enhance the company's capital strength and asset scale, improving its risk resistance and overall competitiveness in the market [3][4] - The company's total assets and net assets will increase post-fundraising, optimizing its financial structure and potentially reducing future debt financing costs [4] Compliance and Governance - The company has established a governance structure in line with listing standards, ensuring independent operation of its shareholder meetings, board of directors, supervisory board, and management [3] - A fundraising management method has been implemented to regulate the storage, use, and supervision of the raised funds, ensuring compliance and risk prevention [3] Conclusion on Feasibility - The fundraising plan aligns with the company's strategic development and complies with relevant policies and regulations, demonstrating both necessity and feasibility [4]

达瑞电子: 第三届董事会第十九次会议决议公告 证券代码：300976 证券简称：达瑞电子 公告编号：2025-015 东莞市达瑞电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 东莞市达瑞电子股份有限公司（以下简称"公司"）第三届董事会第十九次 会议于 2025 年 3 月 24 日在公司会议室以现场结合通讯的方式召开。会议通知于 事 5 人，会议由董事长李清平先生主持，公司监事、高级管理人员列席了会议。 本次会议的召集、召开和表决程序符合《公司法》等法律法规、规范性文件和《公 司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 表决结果：5 票同意，0 票反对，0 票弃权。 三、备查文件 特此公告。 东莞市达瑞电子股份有限公司董事会 经与会董事认真审议，会议形成了如下决议： 余募集资金及剩余超募资金永久补充流动资金的议案》 经审查，董事会认为：本次调整部分募投项目的实施进度是基于项目实际进 展情况作出的审慎决定，符合公司发展战略及募投项目实际建设情况；使用节余 募集资金及剩余超募资金永久补充流动资金，有利于 ...